Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Grove

Showing results (71-80 of 135) with videos related to

Pageof 14
Sort By:
Journal of the American Chemical Society|July 14, 2007
How can a single second sphere amino acid substitution cause reduction midpoint potential changes of hundreds of millivolts?Emine Yikilmaz, Jason Porta, Laurie E Grove, et al.
Arthritis Care & Research|February 14, 2023
Socioeconomic, Disease-Related, and Personal Factors Associated With Participation in Remote Follow-Up in Rheumatoid Arthritis: A Cross-Sectional StudyLiv M V Schougaard, Line R Knudsen, Birgith E Grove, et al.
Clinical and Translational Science|February 29, 2024
Knowledge and attitudes on implementing cardiovascular pharmacogenomic testingCallan Russell, MaryAnn Campion, Megan E Grove, et al.
Journal of Computational Chemistry|February 3, 2016
Focused grid-based resampling for protein docking and mappingArtem B Mamonov, Mohammad Moghadasi, Hanieh Mirzaei, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 3, 2011
Structural conservation of druggable hot spots in protein-protein interfacesDima Kozakov, David R Hall, Gwo-Yu Chuang, et al.
Molecular Biology of the Cell|August 9, 2013
VX-809 corrects folding defects in cystic fibrosis transmembrane conductance regulator protein through action on membrane-spanning domain 1Hong Yu Ren, Diane E Grove, Oxana De La Rosa, et al.
International Journal of Antimicrobial Agents|July 3, 2017
Population pharmacokinetics of cefepime in febrile neutropenia: implications for dose-dependent susceptibility and contemporary dosing regimensNathaniel J Rhodes, Meagan E Grove, Patrick J Kiel, et al.
Leukemia & Lymphoma|June 11, 2014
Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphomaTim Illidge, Reda Bouabdallah, Robert Chen, et al.
NPJ Genomic Medicine|December 15, 2020
Clinical utility of genomic sequencing: a measurement toolkitRobin Z Hayeems, David Dimmock, David Bick, et al.
Journal of Clinical Pharmacology|June 12, 2013
CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignanciesTae H Han, Ajay K Gopal, Radhakrishnan Ramchandren, et al.
Pageof 14

Showing results (71-80 of 135) with videos related to

Sort By:
Pageof 14
Journal of the American Chemical Society|July 14, 2007
How can a single second sphere amino acid substitution cause reduction midpoint potential changes of hundreds of millivolts?Emine Yikilmaz, Jason Porta, Laurie E Grove, et al.
Arthritis Care & Research|February 14, 2023
Socioeconomic, Disease-Related, and Personal Factors Associated With Participation in Remote Follow-Up in Rheumatoid Arthritis: A Cross-Sectional StudyLiv M V Schougaard, Line R Knudsen, Birgith E Grove, et al.
Clinical and Translational Science|February 29, 2024
Knowledge and attitudes on implementing cardiovascular pharmacogenomic testingCallan Russell, MaryAnn Campion, Megan E Grove, et al.
Journal of Computational Chemistry|February 3, 2016
Focused grid-based resampling for protein docking and mappingArtem B Mamonov, Mohammad Moghadasi, Hanieh Mirzaei, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 3, 2011
Structural conservation of druggable hot spots in protein-protein interfacesDima Kozakov, David R Hall, Gwo-Yu Chuang, et al.
Molecular Biology of the Cell|August 9, 2013
VX-809 corrects folding defects in cystic fibrosis transmembrane conductance regulator protein through action on membrane-spanning domain 1Hong Yu Ren, Diane E Grove, Oxana De La Rosa, et al.
International Journal of Antimicrobial Agents|July 3, 2017
Population pharmacokinetics of cefepime in febrile neutropenia: implications for dose-dependent susceptibility and contemporary dosing regimensNathaniel J Rhodes, Meagan E Grove, Patrick J Kiel, et al.
Leukemia & Lymphoma|June 11, 2014
Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphomaTim Illidge, Reda Bouabdallah, Robert Chen, et al.
NPJ Genomic Medicine|December 15, 2020
Clinical utility of genomic sequencing: a measurement toolkitRobin Z Hayeems, David Dimmock, David Bick, et al.
Journal of Clinical Pharmacology|June 12, 2013
CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignanciesTae H Han, Ajay K Gopal, Radhakrishnan Ramchandren, et al.
Pageof 14